Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERACLES: Trastuzumab + Lapatinib or Pertuzumab + T-DM1 in HER2+ mCRC
NCT03225937Phase 2Unknown
- Sponsor
- Fondazione del Piemonte per l'Oncologia
- Start
- Aug 2012
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, lapatinib, pertuzumab, trastuzumab emtansine in metastatic colorectal cancer (mCRC), sponsored by Fondazione del Piemonte per l'Oncologia. Status: unknown.
02
Drugs
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03225937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03225937.